Madrigal Pharmaceuticals (MDGL) Capital Expenditures Growth (3y) (2013 - 2026)
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 60.74% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 27.08% |
| 10 | Madrigal Pharmaceuticals | 15.80 Bn | 14.96 Bn | - | 295.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 295.02% |
| Mar 31, 2026 | 379.10% |
| Dec 31, 2025 | -149.05% |
| Sep 30, 2025 | 196.13% |
| Dec 31, 2024 | 19.95% |
| Sep 30, 2024 | 149.76% |
| Jun 30, 2024 | 303.10% |
| Mar 31, 2024 | 100.94% |
| Dec 31, 2023 | 369.66% |
| Sep 30, 2023 | 383.46% |
| Jun 30, 2023 | 114.41% |
| Mar 31, 2023 | -51.87% |
| Dec 31, 2022 | -67.68% |
| Sep 30, 2022 | 164.48% |
| Jun 30, 2022 | 371.77% |
| Mar 31, 2022 | 8.24% |
| Dec 31, 2021 | 141.73% |
| Sep 30, 2021 | 56.68% |
| Mar 31, 2021 | 253.03% |
| Dec 31, 2020 | -56.91% |